[Accelerated desensitization with Dermatophagoides pteronyssinus in severe asthmatic children. Evaluation after one year of immunotherapy].
An homogeneous group of 17 children with severe chronic asthma were given a rush immunotherapy with standardized Dermatophagoides pteronyssinus extracts. Maintenance dose was injected monthly for one year. Symptom and medication scores as well as functional (lung function tests, specific nasal challenges), immunologic and allergic parameters (skin tests, total serum IgE, specific IgE and IgG4) were recorded before and at the end of the study. Rush immunotherapy was well tolerated in spite of some moderate systemic adverse reactions. Symptom and medication scores improved in 10 children. Nasal and skin sensitivity decreased in respectively 3 and 7 children. However there was no correlation between the improvement of quality of life and laboratory results. This study shows that specific immunotherapy is possible in children with severe asthma. Its efficacy should be assessed by symptom and medication scores.
Paty
E
E
Service d'Allergologie, Hôpital des Enfants-Malades, Paris.
de Blic
J
J
Brunet
D
D
Le Bourgeois
M
M
Garcelon
M
M
Paupe
J
J
Scheinmann
P
P
D000053:Acari; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000818:Animals; D001249:Asthma / Q000188:drug therapy / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D004205:Cromolyn Sodium / Q000627:therapeutic use; D003888:Desensitization, Immunologic / Q000379:methods*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007159:Immunologic Tests; D008297:Male; D012129:Respiratory Function Tests; D013566:Sympathomimetics / Q000627:therapeutic use; D013806:Theophylline / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D007136:Immunoglobulins; D013566:Sympathomimetics; D013806:Theophylline; D004205:Cromolyn Sodium
Désensibilisation accélérée aux Dermatophagoïdes pteronyssinus chez l'asthmatique sévère. Bilan au bout d'un an d'immunothérapie.